<b>Conclusion:</b> Avapritinib provides a favorable initial response in children with RUNX1::RUNX1T1-positive AML harboring KIT mutations, enabling deeper molecular remission; however, response rates decline with prolonged treatment. Here, RUNX1T1 is linked to acute myeloid leukemia.